WO2002032406A3 - Methods and products related to pulmonary delivery of polysaccharides - Google Patents
Methods and products related to pulmonary delivery of polysaccharides Download PDFInfo
- Publication number
- WO2002032406A3 WO2002032406A3 PCT/US2001/032444 US0132444W WO0232406A3 WO 2002032406 A3 WO2002032406 A3 WO 2002032406A3 US 0132444 W US0132444 W US 0132444W WO 0232406 A3 WO0232406 A3 WO 0232406A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polysaccharides
- methods
- pulmonary delivery
- products related
- unformulated
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title abstract 3
- 229920001282 polysaccharide Polymers 0.000 title abstract 3
- 239000005017 polysaccharide Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002224408A AU2002224408B2 (en) | 2000-10-18 | 2001-10-18 | Methods and products related to pulmonary delivery of polysaccharides |
AU2440802A AU2440802A (en) | 2000-10-18 | 2001-10-18 | Methods and products related to pulmonary delivery of polysaccharides |
CA002423469A CA2423469A1 (en) | 2000-10-18 | 2001-10-18 | Methods and products related to pulmonary delivery of polysaccharides |
JP2002535644A JP2004523479A (en) | 2000-10-18 | 2001-10-18 | Methods and products for pulmonary delivery of polysaccharides |
EP01987662A EP1328260A2 (en) | 2000-10-18 | 2001-10-18 | Methods and products related to pulmonary delivery of polysaccharides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24155900P | 2000-10-18 | 2000-10-18 | |
US60/241,559 | 2000-10-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002032406A2 WO2002032406A2 (en) | 2002-04-25 |
WO2002032406A3 true WO2002032406A3 (en) | 2002-10-10 |
Family
ID=22911183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/032444 WO2002032406A2 (en) | 2000-10-18 | 2001-10-18 | Methods and products related to pulmonary delivery of polysaccharides |
Country Status (6)
Country | Link |
---|---|
US (1) | US7709461B2 (en) |
EP (1) | EP1328260A2 (en) |
JP (1) | JP2004523479A (en) |
AU (2) | AU2440802A (en) |
CA (1) | CA2423469A1 (en) |
WO (1) | WO2002032406A2 (en) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1109919A2 (en) * | 1998-08-27 | 2001-06-27 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase i and ii |
WO2000065521A2 (en) * | 1999-04-23 | 2000-11-02 | Massachusetts Institute Of Technology | System and method for polymer notation |
JP2003525946A (en) | 2000-03-08 | 2003-09-02 | マサチューセッツ インスティテュート オブ テクノロジー | Heparinase III and uses thereof |
EP1319183B1 (en) | 2000-09-12 | 2009-03-25 | Massachusetts Institute Of Technology | Methods and products related to low molecular weight heparin |
AU2440802A (en) | 2000-10-18 | 2002-04-29 | Massachusetts Inst Technology | Methods and products related to pulmonary delivery of polysaccharides |
WO2002047696A1 (en) * | 2000-12-16 | 2002-06-20 | Aventis Pharma Deutschland Gmbh | Use of low molecular heparin for treating osteoarthritis |
EP1513502B1 (en) * | 2002-02-18 | 2015-12-30 | Ockham Biotech Limited | Combination therapy for respiratory disorders |
DE60323973D1 (en) * | 2002-02-18 | 2008-11-20 | Univ Southampton | USE OF GLYCOSAMINO LYCANES SUCH AS FOR EXAMPLE. HEPARIN FOR THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD |
WO2003078960A2 (en) | 2002-03-11 | 2003-09-25 | Momenta Pharmaceuticals, Inc. | Analysis of sulfated polysaccharides |
CN100384469C (en) * | 2002-04-01 | 2008-04-30 | Gtc生物治疗学公司 | Treatment of pulmonary disease |
AU2003225182B2 (en) * | 2002-04-25 | 2009-02-26 | Momenta Pharmaceuticals, Inc. | Methods and products for mucosal delivery |
AU2003303301B2 (en) | 2002-05-03 | 2008-08-07 | Massachusetts Institute Of Technology | Delta4,5 glycuronidase and uses thereof |
US7508206B2 (en) * | 2002-05-20 | 2009-03-24 | Massachusetts Institute Of Technology | Method for sequence determination using NMR |
US6962699B2 (en) | 2002-06-03 | 2005-11-08 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from chondroitinase B |
WO2004004636A2 (en) * | 2002-07-03 | 2004-01-15 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis |
JP4606712B2 (en) * | 2003-01-08 | 2011-01-05 | マサチューセッツ インスティテュート オブ テクノロジー | 2-O sulfatase compositions and related methods |
WO2004073729A1 (en) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | Compositions for nasal administration of drug |
KR100974482B1 (en) | 2003-03-27 | 2010-08-10 | 가부시키가이샤 바이오악티스 | Powder medicine applicator for nasal cavity |
WO2004100966A1 (en) * | 2003-05-16 | 2004-11-25 | Bbk Bio Corporation | Preparation for preventing contact of pathogenic matter with living organism |
GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
AU2004278013B2 (en) * | 2003-10-01 | 2009-01-15 | Momenta Pharmaceuticals, Inc. | Polysaccharides for pulmonary delivery of active agents |
US7932365B2 (en) | 2003-11-08 | 2011-04-26 | Pro Thera Biologics, Llc | Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
DE10356346A1 (en) * | 2003-11-28 | 2005-06-23 | TransMIT Gesellschaft für Technologietransfer mbH | Invention relating to the prophylaxis and therapy of diseases caused by or caused by thrombus formation |
US20050192226A1 (en) * | 2004-02-20 | 2005-09-01 | Perenlei Enkhbaatar | Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
EP1718314A1 (en) * | 2004-02-26 | 2006-11-08 | Advanced Ocular Systems Limited | Heparin for the treatment of ocular pathologies |
WO2005087920A2 (en) | 2004-03-10 | 2005-09-22 | Massachusetts Institute Of Technology | Recombinant chondroitinase abc i and uses thereof |
WO2005111627A2 (en) * | 2004-04-15 | 2005-11-24 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
WO2006088491A2 (en) * | 2004-06-29 | 2006-08-24 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
US20060154894A1 (en) * | 2004-09-15 | 2006-07-13 | Massachusetts Institute Of Technology | Biologically active surfaces and methods of their use |
TW200621794A (en) * | 2004-10-06 | 2006-07-01 | Akzo Nobel Nv | Pulmonary administration of an antithrombotic compound |
WO2007053610A2 (en) * | 2005-11-01 | 2007-05-10 | The Regents Of The University Of California | Methods of treating atrial fibrillation wtih pirfenidone |
WO2007075388A2 (en) * | 2005-12-15 | 2007-07-05 | X-Cell Medical Incorporated | Methods of locally treating and preventing cardiac disorders |
US20070154546A1 (en) * | 2005-12-30 | 2007-07-05 | Zhang Jack Y | Sustained release pharmaceutical compositions |
EP2008096A2 (en) * | 2006-04-03 | 2008-12-31 | Massachusetts Institute of Technology | Glycomic patterns for the detection of disease |
EP2404939A3 (en) | 2006-05-25 | 2012-03-21 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
PT2068889T (en) * | 2006-08-10 | 2020-01-30 | Roy C Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
EP2116264B1 (en) | 2006-12-26 | 2017-09-27 | Shin Nippon Biomedical Laboratories, Ltd. | Preparation for transnasal application |
US7842492B2 (en) | 2007-01-05 | 2010-11-30 | Massachusetts Institute Of Technology | Compositions of and methods of using sulfatases from flavobacterium heparinum |
US9139876B1 (en) | 2007-05-03 | 2015-09-22 | Momenta Pharmacueticals, Inc. | Method of analyzing a preparation of a low molecular weight heparin |
DK2291654T3 (en) | 2008-05-28 | 2018-06-14 | Prothera Biologics Inc | PREPARATION AND COMPOSITION OF BLOOD INTER-ALPHA INHIBITOR PROTEINS |
WO2010068308A1 (en) * | 2008-12-10 | 2010-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease |
AU2010236222B2 (en) | 2009-04-16 | 2015-10-15 | Momenta Pharmaceuticals, Inc. | Methods of assessing activity of a polysaccharide composition |
GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
JP2012526726A (en) * | 2009-05-15 | 2012-11-01 | 株式会社新日本科学 | Intranasal pharmaceutical composition with improved pharmacokinetics |
WO2011011797A2 (en) | 2009-07-24 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cytokine compositions and methods of use thereof |
GB2472327B (en) | 2009-07-31 | 2013-03-13 | Shin Nippon Biomedical Lab Ltd | Intranasal granisetron and nasal applicator |
KR20120093932A (en) | 2009-10-10 | 2012-08-23 | 일레븐 바이오테라피틱스, 아이엔씨. | Il-17 family cytokine compositions and uses |
CN102791742B (en) | 2010-01-19 | 2014-12-24 | 动量制药公司 | Evaluating heparin preparations |
WO2012037034A1 (en) | 2010-09-14 | 2012-03-22 | Glycomimetics, Inc. | E-selectin antagonists |
WO2012115952A1 (en) | 2011-02-21 | 2012-08-30 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
PL2794626T6 (en) | 2011-12-22 | 2020-11-02 | Glycomimetics, Inc. | E-selectin antagonist compounds |
EP2827877B1 (en) | 2012-05-15 | 2019-05-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Uses of antagonists of hyaluronan signaling |
JP6445434B2 (en) | 2012-08-09 | 2018-12-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Superkine and synthekine: recycled cytokines with novel and enhanced signaling activity |
WO2014039987A2 (en) | 2012-09-09 | 2014-03-13 | Prothera Biologics, Inc. | Treatment of disease using inter-alpha inhibitor proteins |
US11497593B2 (en) * | 2014-04-13 | 2022-11-15 | R & M Butterworth Pty Ltd. | Livestock treatment method and apparatus |
PL2928476T3 (en) | 2012-12-07 | 2018-07-31 | Glycomimetics, Inc. | Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells |
US20150289962A1 (en) * | 2014-04-13 | 2015-10-15 | R & M Butterworth Pty Ltd. | Livestock Treatment Method and Apparatus |
AU2015355136B2 (en) | 2014-12-03 | 2020-06-25 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
US11291678B2 (en) | 2016-03-02 | 2022-04-05 | Glycomimetics, Inc | Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin |
WO2018031445A1 (en) | 2016-08-08 | 2018-02-15 | Glycomimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4 |
BR112019006642A2 (en) | 2016-10-07 | 2019-07-02 | Glycomimetics Inc | highly potent multimeric e-selectin antagonists |
JP7272956B2 (en) | 2017-03-15 | 2023-05-12 | グリコミメティクス, インコーポレイテッド | Galactopyranosyl-cyclohexyl derivatives as E-selectin antagonists |
US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
JP7275131B2 (en) | 2017-11-30 | 2023-05-17 | グリコミメティクス, インコーポレイテッド | Methods of mobilizing bone marrow-infiltrating lymphocytes and uses thereof |
JP7304863B2 (en) | 2017-12-29 | 2023-07-07 | グリコミメティクス, インコーポレイテッド | Heterobifunctional inhibitors of E-selectin and galectin-3 |
JP7455064B2 (en) | 2018-03-05 | 2024-03-25 | グリコミメティクス, インコーポレイテッド | Methods of treating acute myeloid leukemia and related conditions |
US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
IT202100001349A1 (en) * | 2021-01-25 | 2022-07-25 | Sofar Swiss Sa | COMPOSITION IN THE FORM OF DRY POWDER FOR INHALATION COMPRISING A HYALURONIC ACID AND A CHONDROITIN SULPHATE, USE OF THE COMPOSITION AND INHALER DEVICE CONTAINING THE COMPOSITION |
IT202100021602A1 (en) * | 2021-08-09 | 2023-02-09 | Sofar Spa | Composition in dry powder form for inhalation for use in a method of treatment of inflammation and/or oxidative stress of the respiratory system caused/or by air pollution |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4679555A (en) * | 1984-08-07 | 1987-07-14 | Key Pharmaceuticals, Inc. | Method and apparatus for intrapulmonary delivery of heparin |
WO1993019734A1 (en) * | 1992-04-02 | 1993-10-14 | Baker Norton Pharmaceuticals, Inc. | Method and composition for treating antigen-induced and exercise-induced asthma |
WO1996032149A1 (en) * | 1995-04-14 | 1996-10-17 | Inhale Therapeutic Systems | Pulmonary delivery of aerosolized medicaments |
WO1997006783A1 (en) * | 1995-08-18 | 1997-02-27 | Baker Norton Pharmaceuticals, Inc. | Method and composition for treating asthma |
WO1997035562A1 (en) * | 1996-03-23 | 1997-10-02 | Danbiosyst Uk Limited | Polysaccharide microspheres for the pulmonary delivery of drugs |
WO1998031346A1 (en) * | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4281108A (en) | 1980-01-28 | 1981-07-28 | Hepar Industries, Inc. | Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained |
US4341869A (en) | 1980-08-25 | 1982-07-27 | Massachusetts Institute Of Technology | Process for producing heparinase |
US4443545A (en) | 1980-08-25 | 1984-04-17 | Massachusetts Institute Of Technology | Process for producing heparinase |
US4373023A (en) | 1980-10-14 | 1983-02-08 | Massachusetts Institute Of Technology | Process for neutralizing heparin |
US4396762A (en) | 1981-08-24 | 1983-08-02 | Massachusetts Institute Of Technology | Heparinase derived anticoagulants |
US4551296A (en) | 1982-03-19 | 1985-11-05 | Allied Corporation | Producing high tenacity, high modulus crystalline article such as fiber or film |
CA1226816A (en) | 1982-12-20 | 1987-09-15 | Moses J. Folkman | Inhibition of angiogenesis |
FR2553287B1 (en) | 1983-10-18 | 1986-09-12 | Choay Sa | COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES OR OLIGOSACCHARIDES, ESPECIALLY BASED ON HEPARIN FRACTIONS OR FRAGMENTS, SUITABLE FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS |
US4757056A (en) | 1984-03-05 | 1988-07-12 | Hepar Industries, Inc. | Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions |
FR2584606A1 (en) * | 1985-07-12 | 1987-01-16 | Dropic | USE OF POLY- AND OLIGOSACCHARIDES FOR THE PRODUCTION OF ACTIVE MEDICAMENTS IN THE PATHOLOGIES OF CONNECTIVE TISSUE |
US5262403A (en) | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
US5106734A (en) | 1986-04-30 | 1992-04-21 | Novo Nordisk A/S | Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin |
DK196986D0 (en) | 1986-04-30 | 1986-04-30 | Novo Industri As | PREPARATION OF POLYSACCHARIDES |
US4745105A (en) | 1986-08-20 | 1988-05-17 | Griffin Charles C | Low molecular weight heparin derivatives with improved permeability |
US4942156A (en) | 1986-08-20 | 1990-07-17 | Hepar Industries, Inc. | Low molecular weight heparin derivatives having improved anti-Xa specificity |
US4830013A (en) | 1987-01-30 | 1989-05-16 | Minnesota Mining And Manufacturing Co. | Intravascular blood parameter measurement system |
FR2614026B1 (en) | 1987-04-16 | 1992-04-17 | Sanofi Sa | LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS |
SE8702254D0 (en) | 1987-05-29 | 1987-05-29 | Kabivitrum Ab | NOVEL HEPARIN DERIVATIVES |
US5217705A (en) | 1987-09-25 | 1993-06-08 | Neorx Corporation | Method of diagnosing blood clots using fibrin-binding proteins |
US5169772A (en) | 1988-06-06 | 1992-12-08 | Massachusetts Institute Of Technology | Large scale method for purification of high purity heparinase from flavobacterium heparinum |
IT1234508B (en) | 1988-06-10 | 1992-05-19 | Alfa Wassermann Spa | HEPARIN DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION |
US5204323B1 (en) | 1988-10-06 | 1995-07-18 | Ciba Geigy Corp | Hirudin antidotal compositions and methods |
GB8826448D0 (en) | 1988-11-11 | 1988-12-14 | Thrombosis Res Inst | Improvements in/relating to organic compounds |
US5766573A (en) | 1988-12-06 | 1998-06-16 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
PT93847A (en) | 1989-04-24 | 1990-11-20 | Harvard College | PROCESS FOR THE PREPARATION OF OLIGOSACARIDES OF LOW MOLECULAR WEIGHT DERIVED FROM HEPARIN OR DESPOLYMENED HEPARAN SULFATE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM |
JPH0739339B2 (en) * | 1989-05-01 | 1995-05-01 | アルカーメス コントロールド セラピューティクス,インコーポレイテッド | Method for producing small particles of bioactive molecule |
CA1340966C (en) | 1989-05-19 | 2000-04-18 | Thomas R. Covey | Method of protein analysis |
US5527532A (en) * | 1989-11-13 | 1996-06-18 | President And Fellows Of Harvard College | Extraluminal regulation of the growth and repair of tubular structures in vivo |
IT1237518B (en) | 1989-11-24 | 1993-06-08 | Renato Conti | SUPER-SULFATED HEPARINS |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
US5152784A (en) | 1989-12-14 | 1992-10-06 | Regents Of The University Of Minnesota | Prosthetic devices coated with a polypeptide with type IV collagen activity |
IT1245761B (en) | 1991-01-30 | 1994-10-14 | Alfa Wassermann Spa | PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLICANS ABSORBABLE ORALLY. |
JP3110064B2 (en) | 1991-03-06 | 2000-11-20 | 生化学工業株式会社 | Novel heparitinase, method for producing the same and bacteria producing the same |
US5262325A (en) | 1991-04-04 | 1993-11-16 | Ibex Technologies, Inc. | Method for the enzymatic neutralization of heparin |
HUT67136A (en) | 1991-05-02 | 1995-02-28 | Yeda Res & Dev | Compositions for the prevention and/or treatment of pathological processes |
WO1993005167A1 (en) | 1991-09-06 | 1993-03-18 | Children's Medical Center Corporation | Cell-type specific heparan sulfate proteoglycans and their uses |
US5714376A (en) | 1991-10-23 | 1998-02-03 | Massachusetts Institute Of Technology | Heparinase gene from flavobacterium heparinum |
AU3144993A (en) | 1991-11-21 | 1993-06-15 | Glyko, Inc. | Fluorophore-assisted therapeutic drug monitoring |
GB9202019D0 (en) | 1992-01-30 | 1992-03-18 | Imperial College | Methods and apparatus for assay of sulphated polysaccharides |
IT1254216B (en) | 1992-02-25 | 1995-09-14 | Opocrin Spa | POLYSACCHARIDIC DERIVATIVES OF HEPARIN, EPARAN SULPHATE, THEIR FRACTIONS AND FRAGMENTS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US5453171A (en) | 1992-03-10 | 1995-09-26 | The Board Of Regents Of The University Of Michigan | Heparin-selective polymeric membrane electrode |
GB9206291D0 (en) | 1992-03-23 | 1992-05-06 | Cancer Res Campaign Tech | Oligosaccharides having growth factor binding affinity |
US6673335B1 (en) | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
ES2295087T3 (en) * | 1992-07-24 | 2008-04-16 | Thomas P. Kennedy | NON-ANTICOAGULATING DESULPHATED HEPARINES AS MEDICINES. |
US5389539A (en) | 1992-11-30 | 1995-02-14 | Massachusetts Institute Of Technology | Purification of heparinase I, II, and III from Flavobacterium heparinum |
US5696100A (en) | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
GB9306255D0 (en) | 1993-03-25 | 1993-05-19 | Cancer Res Campaign Tech | Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity |
FR2704861B1 (en) | 1993-05-07 | 1995-07-28 | Sanofi Elf | Purified heparin fractions, process for obtaining them and pharmaceutical compositions containing them. |
US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
WO1995013830A1 (en) | 1993-11-17 | 1995-05-26 | Massachusetts Institute Of Technology | Method for inhibiting angiogenesis using heparinase |
US6013628A (en) | 1994-02-28 | 2000-01-11 | Regents Of The University Of Minnesota | Method for treating conditions of the eye using polypeptides |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US5607859A (en) | 1994-03-28 | 1997-03-04 | Massachusetts Institute Of Technology | Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents |
US5753445A (en) | 1994-04-26 | 1998-05-19 | The Mount Sinai Medical Center Of The City University Of New York | Test for the detection of anti-heparin antibodies |
WO1995030424A1 (en) | 1994-05-06 | 1995-11-16 | Glycomed Incorporated | O-desulfated heparin derivatives, methods of making and uses thereof |
ATE299892T1 (en) | 1994-05-18 | 2005-08-15 | Nektar Therapeutics | METHODS AND COMPOSITIONS FOR DRY POWDER MEDICATION FROM INTERFERONS |
US5681733A (en) | 1994-06-10 | 1997-10-28 | Ibex Technologies | Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum |
US5619421A (en) | 1994-06-17 | 1997-04-08 | Massachusetts Institute Of Technology | Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure |
US5997863A (en) | 1994-07-08 | 1999-12-07 | Ibex Technologies R And D, Inc. | Attenuation of wound healing processes |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
FR2723847A1 (en) | 1994-08-29 | 1996-03-01 | Debiopharm Sa | HEPARIN - BASED ANTITHROMBOTIC AND NON - HEMORRHAGIC COMPOSITIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS. |
US5687090A (en) | 1994-09-01 | 1997-11-11 | Aspen Technology, Inc. | Polymer component characterization method and process simulation apparatus |
WO1996011671A1 (en) | 1994-10-12 | 1996-04-25 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US5569366A (en) | 1995-01-27 | 1996-10-29 | Beckman Instruments, Inc. | Fluorescent labelled carbohydrates and their analysis |
US5618917A (en) | 1995-02-15 | 1997-04-08 | Arch Development Corporation | Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells |
US5763427A (en) | 1995-03-31 | 1998-06-09 | Hamilton Civic Hospitals Research Development Inc. | Compositions and methods for inhibiting thrombogenesis |
US5597811A (en) * | 1995-04-10 | 1997-01-28 | Amerchol Corporation | Oxirane carboxylic acid derivatives of polyglucosamines |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
AU720963B2 (en) | 1995-05-26 | 2000-06-15 | Surmodics, Inc. | Method and implantable article for promoting endothelialization |
US5824299A (en) | 1995-06-22 | 1998-10-20 | President & Fellows Of Harvard College | Modulation of endothelial cell proliferation with IP-10 |
ES2227611T3 (en) | 1995-09-29 | 2005-04-01 | Biomarin Pharmaceutical Inc | USE OF HEPARINES TO DECREASE INFLAMMATORY SPARE PARTS. |
US6217863B1 (en) | 1995-10-30 | 2001-04-17 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from heparinase I |
US5752019A (en) | 1995-12-22 | 1998-05-12 | International Business Machines Corporation | System and method for confirmationally-flexible molecular identification |
BR9709748A (en) | 1996-04-29 | 2000-01-11 | Dura Pharma Inc | Dry powder inhalation method |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
AU3892297A (en) | 1996-07-26 | 1998-02-20 | Ikonos Corporation | Sensor for detecting heparin and other analytes |
WO1998004133A1 (en) | 1996-07-29 | 1998-02-05 | Cavalier Pharmaceuticals | Methods of treating asthma with o-desulfated heparin |
US5767269A (en) | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
US5759767A (en) | 1996-10-11 | 1998-06-02 | Joseph R. Lakowicz | Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids |
US5968822A (en) | 1997-09-02 | 1999-10-19 | Pecker; Iris | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
US6190875B1 (en) | 1997-09-02 | 2001-02-20 | Insight Strategy & Marketing Ltd. | Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
US6268146B1 (en) | 1998-03-13 | 2001-07-31 | Promega Corporation | Analytical methods and materials for nucleic acid detection |
US7056504B1 (en) | 1998-08-27 | 2006-06-06 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase I and II |
EP1109919A2 (en) | 1998-08-27 | 2001-06-27 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase i and ii |
US6291439B1 (en) | 1998-09-02 | 2001-09-18 | Biomarin Pharmaceuticals | Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin |
US6333051B1 (en) | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
WO2000065521A2 (en) | 1999-04-23 | 2000-11-02 | Massachusetts Institute Of Technology | System and method for polymer notation |
JP2003525946A (en) | 2000-03-08 | 2003-09-02 | マサチューセッツ インスティテュート オブ テクノロジー | Heparinase III and uses thereof |
EP1319183B1 (en) | 2000-09-12 | 2009-03-25 | Massachusetts Institute Of Technology | Methods and products related to low molecular weight heparin |
AU2440802A (en) | 2000-10-18 | 2002-04-29 | Massachusetts Inst Technology | Methods and products related to pulmonary delivery of polysaccharides |
US20030008820A1 (en) | 2001-03-27 | 2003-01-09 | Massachusetts Institute Of Technology | Methods and products related to FGF dimerization |
DE60323973D1 (en) | 2002-02-18 | 2008-11-20 | Univ Southampton | USE OF GLYCOSAMINO LYCANES SUCH AS FOR EXAMPLE. HEPARIN FOR THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD |
EP1513502B1 (en) | 2002-02-18 | 2015-12-30 | Ockham Biotech Limited | Combination therapy for respiratory disorders |
AU2003303301B2 (en) | 2002-05-03 | 2008-08-07 | Massachusetts Institute Of Technology | Delta4,5 glycuronidase and uses thereof |
US7508206B2 (en) | 2002-05-20 | 2009-03-24 | Massachusetts Institute Of Technology | Method for sequence determination using NMR |
US6962699B2 (en) | 2002-06-03 | 2005-11-08 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from chondroitinase B |
JP4606712B2 (en) | 2003-01-08 | 2011-01-05 | マサチューセッツ インスティテュート オブ テクノロジー | 2-O sulfatase compositions and related methods |
WO2005087920A2 (en) | 2004-03-10 | 2005-09-22 | Massachusetts Institute Of Technology | Recombinant chondroitinase abc i and uses thereof |
WO2005110438A2 (en) | 2004-04-15 | 2005-11-24 | Massachusetts Institute Of Technology | Methods and products related to the intracellular delivery of polysaccharides |
WO2005111627A2 (en) | 2004-04-15 | 2005-11-24 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
WO2006088491A2 (en) | 2004-06-29 | 2006-08-24 | Massachusetts Institute Of Technology | Methods and compositions related to the modulation of intercellular junctions |
US20060154894A1 (en) | 2004-09-15 | 2006-07-13 | Massachusetts Institute Of Technology | Biologically active surfaces and methods of their use |
WO2006076627A2 (en) | 2005-01-12 | 2006-07-20 | Massachusetts Institute Of Technology | Methods and compositions related to modulating the extracellular stem cell environment |
US20090105463A1 (en) | 2005-03-29 | 2009-04-23 | Massachusetts Institute Of Technology | Compositions of and Methods of Using Oversulfated Glycosaminoglycans |
WO2006105315A2 (en) | 2005-03-29 | 2006-10-05 | Massachusetts Institute Of Technology | Compositions and methods for regulating inflammatory responses |
EP2008096A2 (en) | 2006-04-03 | 2008-12-31 | Massachusetts Institute of Technology | Glycomic patterns for the detection of disease |
-
2001
- 2001-10-18 AU AU2440802A patent/AU2440802A/en active Pending
- 2001-10-18 WO PCT/US2001/032444 patent/WO2002032406A2/en active Application Filing
- 2001-10-18 CA CA002423469A patent/CA2423469A1/en not_active Abandoned
- 2001-10-18 US US09/982,548 patent/US7709461B2/en not_active Expired - Fee Related
- 2001-10-18 AU AU2002224408A patent/AU2002224408B2/en not_active Ceased
- 2001-10-18 JP JP2002535644A patent/JP2004523479A/en active Pending
- 2001-10-18 EP EP01987662A patent/EP1328260A2/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4679555A (en) * | 1984-08-07 | 1987-07-14 | Key Pharmaceuticals, Inc. | Method and apparatus for intrapulmonary delivery of heparin |
WO1993019734A1 (en) * | 1992-04-02 | 1993-10-14 | Baker Norton Pharmaceuticals, Inc. | Method and composition for treating antigen-induced and exercise-induced asthma |
WO1996032149A1 (en) * | 1995-04-14 | 1996-10-17 | Inhale Therapeutic Systems | Pulmonary delivery of aerosolized medicaments |
WO1997006783A1 (en) * | 1995-08-18 | 1997-02-27 | Baker Norton Pharmaceuticals, Inc. | Method and composition for treating asthma |
WO1997035562A1 (en) * | 1996-03-23 | 1997-10-02 | Danbiosyst Uk Limited | Polysaccharide microspheres for the pulmonary delivery of drugs |
WO1998031346A1 (en) * | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
Non-Patent Citations (1)
Title |
---|
M.R. KREITZ NET AL.: "controlled delivery of therapeutics from microporous membranes. II. In vitro degradation and release of heparin-loaded poly (D,L-lactide-co-glycolide)", BIOMATERIALS, vol. 18, no. 24, 1 December 1997 (1997-12-01), barking (GB), pages 1645 - 1651, XP004115836 * |
Also Published As
Publication number | Publication date |
---|---|
US7709461B2 (en) | 2010-05-04 |
AU2440802A (en) | 2002-04-29 |
EP1328260A2 (en) | 2003-07-23 |
US20020128225A1 (en) | 2002-09-12 |
CA2423469A1 (en) | 2002-04-25 |
AU2002224408B2 (en) | 2007-08-23 |
JP2004523479A (en) | 2004-08-05 |
WO2002032406A2 (en) | 2002-04-25 |
AU2002224408B8 (en) | 2002-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002032406A3 (en) | Methods and products related to pulmonary delivery of polysaccharides | |
WO2002083079A3 (en) | Aerosol compositions containing formoterol for delivery to the lungs via nebulization | |
AU2002230700A1 (en) | Using derivative financial products to maximize profit in the airline industry | |
WO2002094342A3 (en) | Compositions for protein delivery via the pulmonary route | |
EP1344780A4 (en) | Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof | |
AU2002231952A1 (en) | Vending system and method with special product dispensed at random in addition to the selected product | |
EP1328214A4 (en) | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications | |
WO2002046191A3 (en) | Urea substituted imidazoquinoline ethers | |
IL151952A0 (en) | Aminopyridine derivatives and pharmaceutical compositions containing the same | |
AU2001230237A1 (en) | Extracts from residues left in the production of wine | |
WO2005007142A3 (en) | Liquid compositions comprising formoterol | |
MA27107A1 (en) | AEROSOL FORMULATIONS FOR THE PULMONARY ADMINISTRATION OF DRUGS TO PRODUCE A SYSTEMIC EFFECT. | |
AU2002210484A1 (en) | Indazoles having an action similar to that of a thyroid hormone, method for the production thereof, and their use in medicaments | |
AU2001285027A1 (en) | System and method for enhanced online transactions using shopping games | |
HUP0402626A3 (en) | Photochemical internalization for virus-mediated molecule delivery into the cyosol | |
WO2002076434A3 (en) | Nicotinic receptor agonists for the treatment of inflammatory diseases | |
WO2002009679A3 (en) | Use of 13-cis retinoic acid for the treatment of emphysema | |
WO2002072571A3 (en) | Pyridinyl pyrazoles useful for the treatment of copd | |
WO2002011724A3 (en) | Neuroprotective 2-pyridinamine compositions and related methods | |
AU2001291543A1 (en) | In vitro human angiogenesis model | |
WO2001030383A3 (en) | Medicament in order to induce tolerance | |
AU2001232390A1 (en) | The method of the game for one to many persons on the online | |
WO2002102332A3 (en) | Methods of manufacturing personal care products | |
WO2001032127A3 (en) | Method and compositions for treating pulmonary diseases | |
IL155853A0 (en) | Substituted cyclohexane derivatives and the use thereof in medicaments for treating cardiovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002224408 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2423469 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002535644 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001987662 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001987662 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |